Literature DB >> 18341374

Where do we stand with targeted therapy of refractory thyroid cancer?--Utility of RECIST criteria.

Furio Pacini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18341374     DOI： 10.1089/thy.2008.0038

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  4 in total

1.  Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines.

Authors:  Eleonore Fröhlich; Inge Fink; Richard Wahl
Journal:  Invest New Drugs       Date:  2008-09-20       Impact factor: 3.850

2.  Knockdown of eIF3a attenuated cell growth in K1 human thyroid cancer cells.

Authors:  Xucai Zheng; Shengying Wang; Shikai Hong; Jianjun Liu; Chenghao Jiang
Journal:  Genes Genomics       Date:  2021-02-17       Impact factor: 1.839

3.  Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.

Authors:  Carmelo Nucera; Matthew A Nehs; Sushruta S Nagarkatti; Peter M Sadow; Michal Mekel; Andrew H Fischer; Paul S Lin; Gideon E Bollag; Jack Lawler; Richard A Hodin; Sareh Parangi
Journal:  Oncologist       Date:  2011-02-25

Review 4.  New therapies for dedifferentiated papillary thyroid cancer.

Authors:  Poupak Fallahi; Valeria Mazzi; Roberto Vita; Silvia Martina Ferrari; Gabriele Materazzi; David Galleri; Salvatore Benvenga; Paolo Miccoli; Alessandro Antonelli
Journal:  Int J Mol Sci       Date:  2015-03-17       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.